Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical comp...
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Vietnamese Organizations Institute of Gastroenterology and Hepatology and ...
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA
— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Indian Organizations Chennai Liver Foundation and FIND Receive the Grant t...
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA
– Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant – – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – – South Korea's Association of Liver Patients and Survivors and the Taiwan re...
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
-- Gilead Awards US$4 Million Globally (Excluding the United States) Through The Gilead ALL4LIVER Grant -- -- World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee -- -- Hong Kong Liver Foundation and Hong Kong Liver Transplant Patients' ...
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations inAfrica, South America, Asia and Oceania, Europe and North America – – Themed 'Test. Link. Prioritize', the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 – SINGAPORE, July 28, ...
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
FOSTER CITY, Calif. and SHANGHAI, June 4, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® (sacituzumab govitecan...
Gilead Sciences' Pulse Survey Highlights Majority of People Living with HIV, Individuals at Risk and HIV Care Prescribers in Asia Pacific Experience Disruptions in HIV Care During COVID-19 Pandemic
HONG KONG, Nov. 30, 2020 /PRNewswire/ -- Gilead Sciences, Inc. today announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on the access and delivery of care in HIV, which includes testing, treatment and prevention, inAsia Pacific. The survey revealed ...
Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program
HONG KONG, Nov. 16, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the recipients of its first Asia HIV Research Scholar Program ("Program"). The Program awards up toUS$130,000 over a period of two years to support innovative HIV scientific research led by early-career ...
Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS & Co-infections Conference
HONG KONG, Oct. 15, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced findings from multiple studies in Asian population that evaluated the safety and efficacy of switching to once-daily, single tablet regimen, Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir...
